| Patient | Irène Joliot-Curie |
|---|---|
| Date of birth | 1968-09-12 |
| Identifiers | MRN HR-RB003-SYN; SSN (made up) 000-03-8841 |
| Document date | 2026-10-08 |
| Author | Solène Marchand-Ellis, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Nausea, two episodes of vomiting, and no bowel movement for four days. [S]
Mrs. Joliot-Curie called this morning and was seen the same day, on day 11 of her first cycle of azacitidine with venetoclax. For three days she has felt queasy for most of the day, and she vomited twice yesterday, about an hour after her evening meal; the venetoclax tablets had been taken with breakfast and stayed down. She has had no bowel movement for four days and feels bloated, without severe pain. She has checked her temperature twice a day as instructed; the highest was 37.4 °C. She has had no chills, cough, sore throat, mouth sores, painful urination, diarrhea, or rectal pain. Her gums ooze a little when she brushes, and she has new small bruises on her shins. She is drinking about a liter and a half a day. She takes posaconazole, acyclovir, levofloxacin and allopurinol as prescribed. [S]
| Element | Detail |
|---|---|
| Onset | Three days ago |
| Character | Constant nausea; vomiting twice after the evening meal; no stool for four days, with bloating |
| Severity | Moderate; eating about half her usual amount |
| Context | Day 11 of cycle 1 of azacitidine with venetoclax; profound neutropenia expected |
| Associated signs and symptoms | No fever (highest 37.4 °C); gum oozing and new bruises |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever or chills |
| Ears, nose, mouth, and throat | Positive | Gums ooze on brushing; no mouth sores or sore throat |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Positive | Nausea, vomiting twice, constipation and bloating; no abdominal pain, diarrhea, rectal pain or bleeding |
| Genitourinary | Negative | No painful urination |
| Integumentary | Positive | Small bruises on both shins; no rash |
| Neurological | Negative | No headache or confusion |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycle | Once daily on days 1 to 7 of each 28-day cycle | Subcutaneous route | 2026-09-28 | active | S |
| Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole) | Ramp-up, then two tablets daily with the 50 mg tablet, with food and water | Oral route | 2026-09-28 to 2026-10-19 | completed | S |
| Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day) | One tablet daily from day 3, with food and water | Oral route | 2026-09-28 to 2026-10-19 | completed | S |
| Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic | 300 mg twice on day 1, then 300 mg once daily with food | Oral route | 2026-09-28 | active | S |
| Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxis | One tablet twice daily | Oral route | 2026-09-28 | active | S |
| Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5 | One tablet daily during profound neutropenia | Oral route | 2026-09-28 to 2026-10-30 | completed | S |
| Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1 | One tablet daily | Oral route | 2026-09-28 to 2026-10-19 | completed | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nausea | One tablet every 8 hours as needed | Oral route | 2026-10-08 | active | S |
| Polyethylene glycol 3350, 17 g powder in a glass of water once daily | 17 g once daily, held for loose stools | Oral route | 2026-10-08 | active | S |
| Sennosides 8.6 mg oral tablet, two tablets at bedtime | Two tablets at bedtime | Oral route | 2026-10-08 to 2026-10-19 | completed | S |
| Potassium chloride 20 mEq extended-release tablet, one tablet twice daily for three days | One tablet twice daily for three days | Oral route | 2026-10-08 to 2026-10-11 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-08 | Body height | 163 | cm | S |
| 2026-10-08 | Body weight | 52.4 | kg | S |
| 2026-10-08 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 2026-10-08 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-10-08 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-10-08 | Heart rate | 98 | /min | S |
| 2026-10-08 | Respiratory rate | 16 | /min | S |
| 2026-10-08 | Body temperature | 37.2 | Cel | S |
| 2026-10-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-08 | Leukocytes [#/volume] in Blood by Automated count | 0.7 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-10-08 | Neutrophils [#/volume] in Blood by Automated count | 0.1 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 2026-10-08 | Hemoglobin [Mass/volume] in Blood | 7.4 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-10-08 | Platelets [#/volume] in Blood by Automated count | 9 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-10-08 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-08 | Potassium [Moles/volume] in Serum or Plasma | 3.3 | mmol/L | 3.5-5.1 mmol/L | Low | S |
| 2026-10-08 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-10-08 | Magnesium [Mass/volume] in Serum or Plasma | 1.8 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-10-08 | Q-T interval corrected | 446 | ms | Above 460 ms is prolonged in women | Normal | S |
Vital signs recorded on 2026-10-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tired but alert; temperature 37.2 °C, pulse 98, blood pressure 106/64, oxygen saturation 97% on room air; weight 52.4 kg, down 1.1 kg |
| Mouth | Dry mucous membranes; a few gum petechiae; no ulcers or thrush |
| Skin | Scattered petechiae and small bruises on both shins; injection sites on the abdomen healing |
| Respiratory | Clear to auscultation |
| Abdomen | Mildly distended and soft, with active bowel sounds; no tenderness or guarding. No rectal examination while neutropenic |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Two months of tiredness, easy bruising and bleeding gums, with pancytopenia and 12 percent blasts on the blood smear; acute leukemia suspected and urgent hematology review booked | resolved | confirmed | D61.818 | S — Synthetic presenting concern at the index visit, superseded by the bone marrow diagnosis two days later; its timing echoes the documented decline in her health (D). |
| Acute myeloid leukemia diagnosed on bone marrow biopsy (34 percent myeloblasts), in a physicist with decades of occupational exposure to ionizing radiation; synthetic modern diagnosis linked to her documented leukemia | active | confirmed | C92.00 | S — Synthetic modern diagnosis and subtype; the type of her real leukemia is not documented. |
| Occupational exposure to ionizing radiation over about four decades: X-ray work early in her career, laboratory work with polonium and other radioactive sources, and a laboratory accident in which a sealed polonium source ruptured on her bench about ten years ago | active | confirmed | Z57.1 | S — Synthetic modern coding of her documented occupational exposure. |
| Pulmonary tuberculosis in her forties, treated to completion; no symptoms of active disease | active | confirmed | Z86.11 | S — Synthetic modern coding of her documented tuberculosis; the treatment details are synthetic. |
| Moderately reduced lung gas transfer (DLCO 58 percent of predicted, FEV1 76 percent) from old tuberculous scarring of the right upper lobe; with performance status 2, it makes her unfit for intensive induction | active | confirmed | R94.2 | S — Synthetic finding on pre-treatment testing. |
| Nausea with vomiting and constipation on day 11 of cycle 1 of azacitidine with venetoclax, without fever, with mild low potassium; managed as an outpatient; resolved | active | confirmed | R11.2 | S — Synthetic treatment side effect; not a historical claim. |
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026); Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023); Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020 (PMID 32658626) (2020)
Follow-up: Nurse phone call tomorrow. Blood count and potassium in three days. Bone marrow and review on day 22. Go to the emergency department at once for a temperature of 38.0 °C or more, abdominal pain, bleeding that does not stop, or vomiting that prevents taking her tablets. Next scheduled visit 2026-10-19: day 22 of cycle 1: bone marrow response, transfusion and infection review, and stopping venetoclax for count recovery. [S]